By Fineline Cube 
Shandong Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia Co., Ltd. (SHA: 603858) announced today that its subsidiary, Luzhou Buchang, will sign an exclusive supply agreement with GOODFELLOW, a leading Philippine pharmaceutical company. Under the deal, Goodfellow will become the sole distributor for Efparepoetin Alfa Injection in the Philippines, handling registration, clinical trials, promotion, distribution and sales of the product in the target region.
Deal Highlights
| Element | Detail |
|---|---|
| Parties | Luzhou Buchang (China) & GOODFELLOW (Philippines) |
| Product | Efparepoetin Alfa Injection – recombinant EPO‑IgG2 fusion protein |
| Scope | Exclusive registration, clinical development, marketing and sales in the Philippines |
| Target Indication | Anemia caused by chronic kidney disease (CKD) in adult dialysis patients on EPO therapy |
| Regulatory Status | Class 1 new biological product; marketing‑authorization application already submitted in China |
About Efparepoetin Alfa
- Composition – Fusion protein of human erythropoietin (EPO) and the Fc fragment of human IgG2.
- Mechanism – Enhances erythropoiesis while reducing immunogenicity, offering a novel therapeutic option for CKD‑related anemia.
- Market Position – First of its kind in China; no comparable products approved for marketing in the country.
Strategic Rationale
- Market Expansion – The Philippines represents a rapidly growing dialysis market with unmet needs for improved anemia management.
- Partner Strength – GOODFELLOW brings local regulatory expertise, established distribution networks, and a strong presence in the Asian‑Pacific region.
- Growth Trajectory – The exclusive arrangement unlocks potential revenue streams while positioning Buchang as a global leader in rare‑disease therapeutics.
Company Background
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) is a China‑listed biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for rare and serious diseases. Its portfolio spans oncology, hematology, and metabolic disorders, supported by a robust regulatory and commercial platform.
Forward‑Looking Statements
This release contains forward‑looking statements regarding the distribution agreement, future sales, and regulatory approvals. These statements are based on current expectations and are subject to risks, uncertainties and changes in market conditions.-Fineline Info & Tech